Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

NCT03089827
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
PPA, Primary Progressive Aphasia, Aphasia, Non-fluent Aphasia, Semantic Dementia, Apraxia of Speech, Primary Progressive Nonfluent Aphasia, Progressive Aphasia
Interventions
C-11 PiB, F-18 FDG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Interventions
11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 2 Interventional Accepts healthy volunteers

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

NCT03503331
Conditions
Alzheimer Disease
Interventions
[C-11]PiB-PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Studies in Corticobasal Syndrome

NCT07000851
Conditions
Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions
C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
Diagnostic Test
Lead sponsor
Jennifer Whitwell
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

NCT06303921
Conditions
Tauopathies
Interventions
11C-M503 PET, Brain MRI, Amyloid PET, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Philadelphia, Pennsylvania
Conditions
Alzheimer's Disease
Interventions
F-18 FDG, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 49 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

NFL LONG Prospective Study

NCT04263337
Conditions
Concussion, Brain
Interventions
[11C] PiB, [18F] PBR111, [18F] Flortaucipir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
3
States / cities
Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Conditions
Alzheimer Disease
Interventions
[11C] Pittsburgh Compound-B (PIB)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Imaging in Demyelinating Diseases

NCT05805839
Conditions
Multiple Sclerosis, Inflammatory Demyelinating Disease
Interventions
C-11 ER176 Radiotracer, C11 Pittsburgh Compound B, PET/CT scan, MRI
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer's Disease
Interventions
C11 PiB, F18 Flutametamol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lewy Body Disease
Interventions
18F-Flortaucipir
Drug
Lead sponsor
Kejal Kantarci
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735
Conditions
Alzheimer Disease, Healthy Aging
Interventions
11C-PiB
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Quantitative Imaging of Brain Glymphatic Function in Humans

NCT04768101
Conditions
Parkinson Disease
Interventions
[11C]-PIB
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

NCT06439992
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri